Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study

详细信息    查看全文

• 作者：Qian Dong (1)
  Xiang-hong Yang (2) (6)
  Yao Zhang (3)
  Wei Jing (1)
  Li-qiang Zheng (4)
  Yun-peng Liu (5)
  Xiu-juan Qu (5)
  
  1. Department of Oncology ; Shengjing Hospital of China Medical University ; Shenyang ; P.R. China
  2. Department of Pathology ; Shengjing Hospital of China Medical University ; Shenyang ; P.R. China
  6. The Shengjing Hospital ; China Medical University ; 36 Sanhao Street ; Heping District ; Shenyang ; 110004 ; P.R. China
  3. Department of Ultrasound ; Shengjing Hospital of China Medical University ; Shenyang ; P.R. China
  4. Library ; Shengjing Hospital of China Medical University ; 36 Sanhao Street Heping District ; Shenyang ; 110004 ; P.R. China
  5. Department of Oncology ; the First Affiliated Hospital of China Medical University ; 155 Nanjing North Street ; Heping District ; Shenyang ; 110001 ; P.R. China
  
• 关键词：Pancreatic ductal adenocarcinoma (PDAC) ; Carbohydrate antigen 19 ; 9 (CA19 ; 9) ; Prognosis ; Overall survival (OS)
• 刊名：World Journal of Surgical Oncology
• 出版年：2014
• 出版时间：December 2014
• 年：2014
• 卷：12
• 期：1
• 全文大小：265 KB
• 参考文献：1. Luo, J, Xiao, L, Wu, C, Zheng, Y, Zhao, N (2013) The incidence and survival rate of population-based pancreatic cancer patients:shanghai cancer registry 2004-2009. PLoS One 8: pp. e76052 CrossRef
  2. Pannala, R, Basu, A, Petersen, GM, Chari, ST (2009) New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. Lancet Oncol 10: pp. 88-95 CrossRef
  3. Barugola, G, Partelli, S, Marcucci, S, Sartori, N, Capelli, P, Bassi, C, Pederzoli, P, Falconi, M (2009) Resectable pancreatic cancer: who really benefits from resection?. Ann Surg Oncol 16: pp. 3316-3322 CrossRef
  4. De La Cruz, MS, Young, AP, Ruffin, MT (2014) Diagnosis and management of pancreatic cancer. Am Fam Physician 89: pp. 626-632
  5. Kobayashi, M, Mizuno, S, Murata, Y, Kishiwada, M, Usui, M, Sakurai, H, Tabata, M, Ii, N, Yamakado, K, Inoue, H, Shiraishi, T, Yamada, T, Isaji, S (2014) Gemcitabine-based chemoradiotherapy followed by surgery for borderline resectable and locally unresectablepancreatic ductal adenocarcinoma: significance of the CA19-9 reduction rate and intratumoral human equilibrative nucleoside transporter 1 expression. Pancreas 43: pp. 350-360 CrossRef
  6. Tempero, MA, Uchida, E, Takasaki, H, Burnett, DA, Steplewski, Z, Pour, PM (1987) Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. Cancer Res 47: pp. 5501-5503
  7. Berger, AC, Meszoely, IM, Ross, EA, Watson, JC, Hoffman, JP (2004) Undetectable preoperative levels of serum CA 19-9 correlate with improved survival for patients with resectable pancreatic adenocarcinoma. Ann Surg Oncol 11: pp. 644-649 CrossRef
  8. Distler, M, Pilarsky, E, Kersting, S, Gr眉tzmann, R (2013) Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study. Int J Surg 11: pp. 1067-1072 CrossRef
  9. Mehta, J, Prabhu, R, Eshpuniyani, P, Kantharia, C, Supe, A (2010) Evaluating the efficacy of tumor markers CA 19-9 and CEA to predict operability and survival in pancreatic malignancies. Trop Gastroenterol 31: pp. 190-194
  10. Waraya, M, Yamashita, K, Katagiri, H, Ishii, K, Takahashi, Y, Furuta, K, Watanabe, M (2009) Preoperative serum CA19-9 and dissected peripancreatic tissue margin as determiners of long-term survival in pancreatic cancer. Ann Surg Oncol 16: pp. 1231-1240 CrossRef
  11. Sugiura, T, Uesaka, K, Kanemoto, H, Mizuno, T, Sasaki, K, Furukawa, H, Matsunaga, K, Maeda, A (2012) Serum CA19-9 is significant predictor among preoperative parameters for early recurrence after resection of pancreatic adenocarcinoma. J Gastrointest Surg 16: pp. 977-985 CrossRef
  12. Ueda, M, Endo, I, Nakashima, M, Minami, Y, Takeda, K, Matsuo, K, Nagano, Y, Tanaka, K, Ichikawa, Y, Togo, S, Kunisaki, C, Shimada, H (2009) Prognostic factors after resection of pancreatic cancer. World J Surg 33: pp. 104-110 CrossRef
  13. Barton, JG, Bois, JP, Sarr, MG, Wood, CM, Qin, R, Thomsen, KM, Kendrick, ML, Farnell, MB (2009) Predictive and prognostic value of CA19-9 in resected pancreatic adenocarcinoma. J Gastrointest Surg 13: pp. 2050-2058 CrossRef
  14. Hartwig, W, Strobel, O, Hinz, U, Fritz, S, Hackert, T, Roth, C, B眉chler, MW, Werner, J (2013) CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy. Ann Surg Oncol 20: pp. 2188-2196 CrossRef
  15. Hirakawa, T, Nakata, B, Amano, R, Kimura, K, Shimizu, S, Ohira, G, Yamada, N, Ohira, M, Hirakawa, K (2011) HER3 overexpression as an independent indicator of poor prognosis for patients with curatively resected pancreatic cancer. Oncology 81: pp. 192-198 CrossRef
  16. Haglund, C, Roberts, PJ, Kuusela, P, Scheinin, TM, M盲kel盲, O, Jalanko, H (1986) Evaluation of CA 19-9 as a serum tumour marker in pancreatic cancer. Br J Cancer 53: pp. 197-202 CrossRef
  17. Edge, SB, Byrd, DR, Compton, CC (2010) AJCC cancer staging manual. Springer, New York
  18. Schlieman, MG, Ho, HS, Bold, RJ (2003) Utility of tumor markers in determining respectability of pancreatic cancer. Arch Surg 138: pp. 951-955 CrossRef
  19. Kondo, N, Murakami, Y, Uemura, K, Hayashidani, Y, Sudo, T, Hashimoto, Y, Nakashima, A, Sakabe, R, Shigemoto, N, Kato, Y, Ohge, H, Sueda, T (2010) Prognostic impact of perioperative serum CA 19-9 levels in patients with resectable pancreatic cancer. Ann Surg Oncol 17: pp. 2321-2329 CrossRef
  20. Ferrone, CR, Finkelstein, DM, Thayer, SP, Muzikansky, A, Fernandez-delCastillo, C, Warshaw, AL (2006) Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol 24: pp. 2897-2902 CrossRef
  21. Goonetilleke, KS, Siriwardena, AK (2007) Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol 33: pp. 266-270 CrossRef
  22. Hartwig, W, Hackert, T, Hinz, U, Gluth, A, Bergmann, F, Strobel, O, B眉chler, MW, Werner, J (2011) Pancreatic cancer surgery in the new millennium: better prediction of outcome. Ann Surg 254: pp. 311-319 CrossRef
  23. Kang, CM, Kim, JY, Choi, GH, Kim, KS, Choi, JS, Lee, WJ, Kim, BR (2007) The use of adjusted preoperative CA 19-9 to predict the recurrence of resectable pancreatic cancer. J Surg Res 140: pp. 31-35 CrossRef
  24. Kalthoff, H, Kreiker, C, Schmiegel, WH, Greten, H, Thiele, HG (1986) Characterization of CA19-9 bearing mucins as physiological exocrine pancreatic secretion products. Cancer Res 46: pp. 3605-3607
  25. Rahbari, NN, Bork, U, Hinz, U, Leo, A, Kirchberg, J, Koch, M, B眉chler, MW, Weitz, J (2012) AB0 blood group and prognosis in patients with pancreatic cancer. BMC Cancer 12: pp. 319 CrossRef
  26. Berger, AC, Garcia, M, Hoffman, JP, Regine, WF, Abrams, RA, Safran, H, Konski, A, Benson, AB, MacDonald, J, Willett, CG (2008) Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. J Clin Oncol 26: pp. 5918-5922 CrossRef
  27. Kinsella, TJ, Seo, Y, Willis, J, Stellato, TA, Siegel, CT, Harpp, D, Willson, JK, Gibbons, J, Sanabria, JR, Hardacre, JM, Schulak, JP (2008) The impact of resection margin status and postoperative CA19-9 levels on survival and patterns of recurrence after postoperative high-dose radiotherapy with 5-FU-based concurrent chemotherapy for resectable pancreatic cancer. Am J Clin Oncol 31: pp. 446-453 CrossRef
  28. Chang, DK, Johns, AL, Merrett, ND, Gill, AJ, Colvin, EK, Scarlett, CJ, Nguyen, NQ, Leong, RW, Cosman, PH, Kelly, MI, Sutherland, RL, Henshall, SM, Kench, JG, Biankin, AV (2009) Margin clearance and outcome in resected pancreatic cancer. J Clin Oncol 27: pp. 2855-2862 CrossRef
  29. Kim, J, Reber, HA, Dry, SM, Elashoff, D, Chen, SL, Umetani, N, Kitago, M, Hines, OJ, Kazanjian, KK, Hiramatsu, S, Bilchik, AJ, Yong, S, Shoup, M, Hoon, DS (2006) Unfavourable prognosis associated with K-ras gene mutation in pancreatic cancer surgical margins. Gut 55: pp. 1598-1605 CrossRef
  30. Siegel, R, Naishadham, D, Jemal, A (2012) Cancer statistics, 2012. CA Cancer J Clin 62: pp. 10-29 CrossRef
  
• 刊物主题：Surgical Oncology;
• 出版者：BioMed Central
• ISSN：1477-7819

文摘

Background Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive human cancers. Several studies have reported that the carbohydrate antigen 19-9 (CA19-9) level is a useful marker for predicting the prognosis for PDAC after resection. However, the cutoff value of CA19-9 used to predict prognosis varied among these reports. The aims of this study were to evaluate whether the serum CA19-9 level is a significant predictor for survival and to determine the optimal cutoff value of CA19-9 for predicting prognosis. Methods A total of 120 consecutive patients who underwent surgery for potentially resectable primary PDAC were retrospectively analyzed. The variables included the following: age, sex, the location of the tumor, the maximal tumor size, the histological differentiation, the margin status, the tumor stage, serum CA19-9 levels, and serum total bilirubin (TBil) levels. Results The overall 1-year survival rate was 62.5%. The receiver operating characteristic (ROC) curve indicated a significant result for the level of CA19-9 in predicting death within 1 year after surgery (Area under the curve (AUC), 0.612; 95% confidence interval (CI), 0.505-0.720; P = 0.040). The optimal cutoff point was 338.45 U/mL (sensitivity, 60.0%; specificity, 66.7%; accuracy, 64.2%). The strongest univariate predictor among the categorized CA19-9 values was CA19-9 greater than or equal to 338.45 U/mL. In the multivariate Cox proportional hazards mode analysis, the serum CA19-9 level, age and the histological differentiation were significant independent prognostic factors that were associated with the overall survival. Conclusions The preoperative elevated CA19-9 level is a promising independent factor for predicting a poor prognosis in PDAC, and the optimal cutoff value is 338.45 U/mL.